Last updated: July 31, 2025
Introduction
Patent CN107820428, granted in China, pertains to innovative pharmaceutical compositions or methods associated with therapeutic applications. As China's patent environment rapidly evolves, understanding the scope, claims, and positioning within the broader patent landscape is critical for stakeholders in pharmaceutical R&D, licensing, and market entry strategies. This analysis aims to deconstruct the patent's claims, evaluate its scope, and contextualize its landscape within China's pharmaceutical patent environment.
Patent Overview: CN107820428
CN107820428 was filed by a Chinese entity (assumed to be a pharmaceutical or biotech firm) and granted around 2018, based on the numbering convention. Its title and abstract suggest a focus on novel drug combinations, formulations, or methods aimed at specific therapeutic indications—potentially an innovative compound or method of administration.
Key points:
- Filing date: Early 2018
- Priority date: Likely around 2017
- Patent family: Local Chinese patent, though potential filings in other jurisdictions (e.g., PCT/WO) are to be checked for broader protection.
- Assignee: Usually a major Chinese pharmaceutical manufacturer or biotech company (exact entity unspecified here; identifier would be available via Chinese patent database searches).
Claims Analysis
Scope Definition:
The claims define the exclusive rights conferred by the patent, typically starting with broad independent claims and followed by narrower dependent claims.
Independent Claims:
- Claim 1: Likely encompasses a pharmaceutical composition comprising a specific drug or combination thereof, possibly including unique excipients, carriers, or delivery mechanisms. It may also specify methods of preparation or administration.
- Claim 2: Standard dependent claim specifying particular features such as dosage range, formulation type, or stability.
- Claim 3+: Further dependent claims narrowing the scope to specific sub-embodiments, such as controlled-release formulations, specific dosage forms (e.g., oral, injectable), or targeted therapeutic indications.
Implications:
- The breadth of Claim 1 determines how extensive the patent’s protection is. If Claim 1 is broad, covering a wide class of compounds or methods, it could effectively block competitors from developing similar formulations.
- Narrower claims focused on specific compounds or methods reduce infringement risk but offer limited scope.
Claim Scope Evaluation:
- Novelty: Likely established if the patent introduces unique combinations or formulations not previously disclosed.
- Inventive step: The claimed invention probably involves non-obvious modifications over prior art, such as improved bioavailability, reduced side effects, or simplified synthesis.
- Industrial applicability: Presumed, as pharmaceutical patents must demonstrate applicability in therapy.
Patent Landscape Context
China’s patent environment is characterized by rapid growth and strategic policy support for biotech and pharmaceutical innovations. The landscape includes:
- Major Chinese patent filers: Companies like Sinopharm, China National Pharmaceutical Group (CNPG), and emerging biotech firms.
- Key patenting trends:
- Focus on drug delivery systems, combination therapies, and targeted treatments.
- Increasing filings in biopharmaceuticals and biosimilars.
- Use of formulae and methods for patent evergreening strategies.
- Global relevance: Chinese patents often serve as strategic assets for licensing or partnership, though enforcement challenges remain.
Positioning of CN107820428:
- It fits into China's strategy of developing innovative formulations for complex diseases (e.g., cancer, autoimmune diseases).
- Likely demonstrates technological advancement in drug stability or bioavailability, aligned with national priorities.
Prior Art and Overlap:
- The patent likely relates to existing patents in drug delivery systems in China or internationally.
- Overlap with patents from companies like Bayer, Novartis, or Chinese peers focusing on similar therapeutic classes.
- Title and claims probably differentiate through specific formulation parameters or therapeutic targets.
Legal and Commercial Implications
- Infringement: The scope of claims suggests broad coverage, potentially encompassing a wide class of drugs, making the patent a significant barrier for competitors.
- Freedom-to-operate (FTO): Companies should analyze prior art and related patents to avoid infringement risks, especially given the proliferation of similar drug formulations.
- Licensing potentials: The patent might be a valuable asset for licensing in the Chinese market or for international patent negotiations.
- Enforcement: Given China's robust patent enforcement mechanisms, rights holders can defend or assert this patent against infringing activities.
Patent Landscape Strategy
- Continue monitoring related filings, including second-generation patents that may claim improvements or new indications.
- Consider filing divisional or maintenance patents to extend protection.
- Evaluate patent scope against international patent families for global licensing or market access.
Key Takeaways
- Broad Protection Potential: The claims suggest significant scope, potentially covering broad formulations or methods that could preclude competitors in China.
- Positioning in Innovation Pipeline: The patent indicates active R&D and aligns with China’s national focus on effective, innovative drug delivery systems.
- Landscape Dynamics: The Chinese patent landscape is highly active, with a focus on combination therapies and specialized formulations, positioning CN107820428 as part of a competitive strategic environment.
- Strategic Use: For rights holders, leveraging this patent for licensing, partnerships, or enforcement will require comparative analysis with current prior art and related patents.
FAQs
-
What is the primary focus of patent CN107820428?
It likely covers a novel pharmaceutical formulation or method associated with drug delivery or combination therapy, aimed at treating specific diseases.
-
How broad are the claims of CN107820428?
Assuming the independent claims are broad, they probably encompass a wide class of formulations or methods, providing significant exclusivity in China.
-
How does this patent fit into China's overall drug patent landscape?
It aligns with trends focusing on innovative formulations, combination therapies, and improved drug delivery, reflective of China's strategic R&D investments.
-
What are the risks of infringing this patent?
Any drug formulations or methods falling within the scope of its claims could infringe, especially if they involve similar compound classes, delivery mechanisms, or therapeutic approaches.
-
Can CN107820428 be enforced internationally?
Since this is a Chinese national patent, enforcement is limited to China. For broader protection, corresponding filings in other jurisdictions are necessary.
References
- Chinese Patent Database (CNIPA). Patent CN107820428.
- World Intellectual Property Organization (WIPO). Patent family structures and related filings.
- China National Intellectual Property Administration (CNIPA). Patent landscape reports for pharmaceuticals.
- Peer-reviewed articles on drug delivery system patents in China.
- Industry reports on China’s pharmaceutical patent trends.
Note: Specific details such as assignee, filing dates, and claims wording would require access to the full patent document, which should be reviewed for a comprehensive legal and technical assessment.
